Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

Jae Yong Kim, Kyeongseok Jeon, Jung Joo Hong, Sang In Park, Hyeonggon Cho, Hyo Jung Park, Hye Won Kwak, Hyeong Jun Park, Yoo Jin Bang, Yu Sun Lee, Seo Hyeon Bae, So Hee Kim, Kyung Ah Hwang, Dae Im Jung, Seong Hoo Cho, Sang Hwan Seo, Green Kim, Hanseul Oh, Hwal Yong Lee, Ki Hyun KimHee Young Lim, Pyeonghwa Jeon, Joo Yeon Lee, Junho Chung, Sang Myeong Lee, Hae Li Ko, Manki Song, Nam Hyuk Cho, Young suk Lee, So Hee Hong, Jae Hwan Nam

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.

Original languageEnglish
Article number8189
JournalScientific Reports
Issue number1
StatePublished - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).


Dive into the research topics of 'Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV'. Together they form a unique fingerprint.

Cite this